# Association of Clinical Severity in Autism Spectrum Disorder with Biomolecules Involved in Lipid Metabolism, Inflammation and miRNAs

**Authors:** Maria Gevezova, Michael Maes, Iliana Pacheva, Nikolay Mehterov, Zdravko Ivanov, Elena Timova, Stefka Spassieva, Erhard Bieberich, Maria Kazakova, Ivan Ivanov, Victoria Sarafian

PMC · DOI: 10.3390/biom16020303 · Biomolecules · 2026-02-14

## TL;DR

This study explores how changes in lipid metabolism, inflammation, and miRNA expression relate to the severity of autism in children.

## Contribution

The study identifies specific gene and miRNA expression patterns correlated with clinical severity in ASD patients.

## Key findings

- ASD patients showed increased mRNA levels of CerS1, SMPD5, COX2, YKL40, LAMP1, and LAMP2 compared to healthy controls.
- Decreased expression of miRNA-181a-5p was observed in ASD patients.
- COX2, miRNA-143-3p, CerS1, CerS6, and age explained 48% of the variance in ADOS scores.

## Abstract

Autism spectrum disorder (ASD) is a heterogeneous neurological condition with an unclear etiology and pathogenesis. In recent years, studies have identified changes in lipid metabolism, inflammation, mitochondrial dysfunction, and mitophagy in patients with ASD. However, the specific interactions between these molecular signatures and their clinical applications in ASD remain largely unexplored. The aim of our study is to search for correlations between changes in gene and miRNA expression and the clinical characteristics of ASD. The investigation included a cohort of children with idiopathic ASD and healthy controls (HC). Diagnosis was established based on ADOS assessment (autism diagnostic observation schedule). Gene expression levels of sphingomyelin phosphodiesterases (SMPD1 and 5), ceramide synthases (CerS1 and 6), cyclooxygenase-2 (COX2), chitinase-3-like protein 1 (YKL40), and lysosome-associated membrane proteins 1 and 2 (LAMP1 and 2) were assessed using qPCR. The TaqMan assay was used for the quantification of miR-143-3p and miR-181a-5p. Our findings provide novel data on altered expression profiles of molecules related to lipid metabolism and LAMP1/2 in patients with ASD. We observed increased mRNA levels of CerS1, SMPD5, COX2, YKL40, LAMP1, and LAMP2 and decreased expression of miRNA-181a-5p in ASD patients compared to HC. Additionally, we identified a correlation between CerS1, CerS6, COX2, and miRNA-143-5p with ADOS scores. Multiple regression analysis revealed that 48.0% of the variance in the total ADOS score was explained by the combined effects of COX2, miRNA-143-3p, CerS1, CerS6 and age. These results provide new insights into the molecular alterations associated with ASD and may reinforce future studies aimed at clarifying their functional relevance.

## Linked entities

- **Genes:** SMPD1 (sphingomyelin phosphodiesterase 1) [NCBI Gene 6609], SMPD5 (sphingomyelin phosphodiesterase 5 (pseudogene)) [NCBI Gene 392275], CERS1 (ceramide synthase 1) [NCBI Gene 10715], CERS6 (ceramide synthase 6) [NCBI Gene 253782], COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513], CHI3L1 (chitinase 3 like 1) [NCBI Gene 1116], LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916], LAMP2 (lysosome associated membrane protein 2) [NCBI Gene 3920]
- **Diseases:** autism spectrum disorder (MONDO:0005258)

## Full-text entities

- **Genes:** IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, PC (pyruvate carboxylase) [NCBI Gene 5091] {aka PCB}, CERS2 (ceramide synthase 2) [NCBI Gene 29956] {aka L3, LASS2, SP260, TMSG1}, CHI3L1 (chitinase 3 like 1) [NCBI Gene 1116] {aka ASRT7, CGP-39, GP-39, GP39, HC-gp39, HCGP-3P}, NTF3 (neurotrophin 3) [NCBI Gene 4908] {aka HDNF, NGF-2, NGF2, NT-3, NT3}, ACTB (actin beta) [NCBI Gene 60] {aka BKRNS, BNS, BRWS1, CSMH, DDS1, PS1TP5BP1}, CERS1 (ceramide synthase 1) [NCBI Gene 10715] {aka EPM8, LAG1, LASS1, UOG1}, FGF21 (fibroblast growth factor 21) [NCBI Gene 26291], SMPD5 (sphingomyelin phosphodiesterase 5 (pseudogene)) [NCBI Gene 392275] {aka MA-nSMase, SMPD5P}, Lamp1 (lysosomal-associated membrane protein 1) [NCBI Gene 16783] {aka CD107a, LGP-120, LGP-A, Lamp-1, P2B, Perk}, CERS6 (ceramide synthase 6) [NCBI Gene 253782] {aka LASS6}, LAMP3 (lysosome associated membrane protein 3) [NCBI Gene 27074] {aka CD208, DC LAMP, DC-LAMP, DCLAMP, LAMP, LAMP-3}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, Tfeb (transcription factor EB) [NCBI Gene 21425] {aka Tcfeb, bHLHe35}, SMPD1 (sphingomyelin phosphodiesterase 1) [NCBI Gene 6609] {aka ASM, ASMASE, NPD}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, Lamp2 (lysosomal-associated membrane protein 2) [NCBI Gene 16784] {aka CD107b, LGP-B, Lamp II, Lamp-2, Lamp-2a, Lamp-2b}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, SNAP25 (synaptosome associated protein 25) [NCBI Gene 6616] {aka CMS18, DEE117, RIC-4, RIC4, SEC9, SNAP}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, MIR143 (microRNA 143) [NCBI Gene 406935] {aka MIRN143, mir-143}, LAMP2 (lysosome associated membrane protein 2) [NCBI Gene 3920] {aka CD107b, DND, LAMP-2, LAMPB, LGP-96, LGP110}, RNU6-1 (RNA, U6 small nuclear 1) [NCBI Gene 26827] {aka RNU6, RNU6A, RP103, U6, U6-1}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, SNORD48 (small nucleolar RNA, C/D box 48) [NCBI Gene 26801] {aka RNU48, U48}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}
- **Diseases:** cerebellar ataxia (MESH:D002524), embryonic lethality (MESH:D020964), epilepsy (MESH:D004827), intellectual disability (MESH:D008607), abnormalities in lipid metabolism (MESH:D052439), ADOS (MESH:C538387), agitation (MESH:D011595), infections (MESH:D007239), cerebral ischemic injury (MESH:D017202), immune dysfunction (MESH:D007154), gastrointestinal disorders (MESH:D005767), colitis (MESH:D003092), neuronal damage (MESH:D009410), immune dysregulation (OMIM:614878), synaptic dysfunction (MESH:C536122), multiple sclerosis (MESH:D009103), neurodevelopmental disorder (MESH:D002658), cognitive impairments (MESH:D003072), neurodegeneration (MESH:D019636), neurodevelopmental diseases (MESH:D004194), injury to (MESH:D014947), Inflammation (MESH:D007249), pain (MESH:D010146), ASD (MESH:D000067877), Niemann-Pick Disease type A and B (MESH:D052537), mitochondrial dysfunction (MESH:D028361), Mental Disorders (MESH:D001523), Alzheimer's disease (MESH:D000544), overactivity (MESH:D053201), mitochondrial disfunction (MESH:D057215), diabetes mellitus (MESH:D003920), sensory abnormalities (MESH:D012678), lysosomal storage diseases (MESH:D016464), neurodevelopmental abnormalities (MESH:D063647), autism (MESH:D001321), bronchial asthma (MESH:D001249), central nervous system (CNS) disorders (MESH:D002493), progressive myoclonic epilepsy type 8 (MESH:D020191), schizophrenia (MESH:D012559), neuroinflammation (MESH:D000090862), neuronal dysfunction (MESH:D009461), major depressive disorder (MESH:D003865)
- **Chemicals:** AM1907 (-), sphingomyelin (MESH:D013109), carnitine (MESH:D002331), glycerol (MESH:D005990), carbohydrate (MESH:D002241), fatty acid (MESH:D005227), medium-chain triglycerides (MESH:C000709826), docosahexaenoic acid (MESH:D004281), sucrose (MESH:D013395), Lipid (MESH:D008055), Sphingolipid (MESH:D013107), phosphocholine (MESH:D010767), glucose (MESH:D005947), ROS (MESH:D017382), oxygen (MESH:D010100), lactate (MESH:D019344), omega-3 fatty acids (MESH:D015525), NH4Cl (MESH:D000643), prostaglandins (MESH:D011453), EDTA (MESH:D004492), R(+)-methanandamide (MESH:C088155), sphingosine 1-phosphate (MESH:C060506), arachidonic acid (MESH:D016718), Trizol (MESH:C411644), PGE2 (MESH:D015232), glutamate (MESH:D018698), Ceramides (MESH:D002518)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** rs2745557

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938623/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938623/full.md

## References

111 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938623/full.md

---
Source: https://tomesphere.com/paper/PMC12938623